Fuller & Thaler Asset Management Inc. Increases Stock Position in Encompass Health Corporation $EHC

Fuller & Thaler Asset Management Inc. raised its holdings in Encompass Health Corporation (NYSE:EHC) by 11.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,541,477 shares of the company’s stock after purchasing an additional 163,400 shares during the quarter. Fuller & Thaler Asset Management Inc.’s holdings in Encompass Health were worth $156,121,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Colonial Trust Co SC purchased a new stake in Encompass Health in the 4th quarter valued at approximately $29,000. Transce3nd LLC purchased a new stake in shares of Encompass Health during the 4th quarter worth approximately $40,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Encompass Health by 749.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 416 shares of the company’s stock worth $42,000 after acquiring an additional 367 shares in the last quarter. Arlington Trust Co LLC boosted its stake in shares of Encompass Health by 22.9% during the 1st quarter. Arlington Trust Co LLC now owns 671 shares of the company’s stock worth $68,000 after acquiring an additional 125 shares in the last quarter. Finally, Johnson Financial Group Inc. purchased a new stake in shares of Encompass Health during the 4th quarter worth approximately $72,000. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Price Performance

EHC stock opened at $120.35 on Monday. Encompass Health Corporation has a 1 year low of $87.85 and a 1 year high of $123.13. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.06 and a current ratio of 1.06. The stock’s 50 day moving average price is $116.13 and its 200 day moving average price is $109.63. The firm has a market cap of $12.12 billion, a P/E ratio of 23.55, a PEG ratio of 2.10 and a beta of 0.86.

Encompass Health (NYSE:EHC) last posted its earnings results on Monday, August 4th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.20. Encompass Health had a return on equity of 17.83% and a net margin of 9.22%. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the prior year, the company earned $1.11 EPS. Encompass Health’s revenue was up 12.0% on a year-over-year basis. On average, sell-side analysts expect that Encompass Health Corporation will post 4.8 earnings per share for the current fiscal year.

Encompass Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Wednesday, October 1st will be issued a $0.19 dividend. This is a boost from Encompass Health’s previous quarterly dividend of $0.17. The ex-dividend date is Wednesday, October 1st. This represents a $0.76 annualized dividend and a yield of 0.6%. Encompass Health’s payout ratio is presently 13.31%.

Insiders Place Their Bets

In other Encompass Health news, CEO Mark J. Tarr sold 118,384 shares of the business’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total value of $14,387,207.52. Following the completion of the transaction, the chief executive officer directly owned 527,070 shares in the company, valued at approximately $64,054,817.10. The trade was a 18.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 2.10% of the company’s stock.

Wall Street Analyst Weigh In

EHC has been the topic of several research analyst reports. KeyCorp boosted their price target on Encompass Health from $122.00 to $135.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 27th. UBS Group raised their target price on shares of Encompass Health from $130.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, August 6th. Barclays raised their target price on shares of Encompass Health from $118.00 to $129.00 and gave the company an “overweight” rating in a report on Friday, April 25th. Stephens upgraded shares of Encompass Health from an “overweight” rating to a “strong-buy” rating and set a $135.00 target price for the company in a report on Thursday, June 5th. Finally, Truist Financial set a $140.00 target price on Encompass Health and gave the company a “buy” rating in a research note on Thursday. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $134.00.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.